How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Cervical Intraepithelial Neoplasia Market
- By Grade of Cervical Intraepithelial Neoplasia: CIN 1 (Mild Dysplasia), CIN 2 (Moderate Dysplasia), CIN 3 (Severe Dysplasia/CIS)
- By Diagnostic Method: Colposcopy, Pap Smear Cytology, HPV DNA Testing, Biopsy and Histopathology
- By Treatment Type: Watchful Waiting/Observation, Cryotherapy, Loop Electrosurgical Excision Procedure (LEEP), Cold Knife Conization, Laser Therapy
- By Patient Demographics: Reproductive Age Women, Postmenopausal Women, Immunocompromised Patients (e.g., HIV Positive)
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - CIN 1 (Mild Dysplasia) leads By Grade of Cervical Intraepithelial Neoplasia at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 14 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 268 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.162 →
- 11 Company Profiles 14 players: SWOT & benchmarking p.170 →
Full report · locked preview
Everything inside the Cervical Intraepithelial Neoplasia Market report
A complete, evidence-based study - 11 chapters and 112 sections covering market size, segmentation across 4 axes, regional analysis and 14 company profiles, forecast to 2033.
Segmentation covered
Grade of Cervical Intraepithelial Neoplasia 3
Diagnostic Method 4
Treatment Type 5
Patient Demographics 3
Companies profiled
Hologic Inc.
QIAGEN N.V.
Roche Diagnostics
Becton
Dickinson and Company (BD)
Abbott Laboratories
Thermo Fisher Scientific Inc.
Siemens Healthineers
PerkinElmer Inc.
F. Hoffmann-La Roche AG
Bio-Rad Laboratories Inc.
Genomica S.A.U.
+2 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
14 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Hologic Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →QIAGEN N.V.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Roche Diagnostics
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Becton
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Dickinson and Company (BD)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Abbott Laboratories
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Thermo Fisher Scientific Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Siemens Healthineers
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →PerkinElmer Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →F. Hoffmann-La Roche AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Bio-Rad Laboratories Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Genomica S.A.U.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.220 →Myriad Genetics
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$8,620M by 2033 · 8.3% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- CIN 1 (Mild Dysplasia)68.4
- CIN 2 (Moderate Dysplasia)17.0
- CIN 3 (Severe Dysplasia/CIS)14.6
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,503M → $2,877M · 8.5%
Europe$1,047M → $1,833M · 7.3%
Asia Pacific$956.1M → $1,885M · 8.9%
Latin America$591.9M → $1,250M · 9.8%
Middle East and Africa$455.3M → $947.1M · 9.6%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →8.272026
8.262027
8.272028
8.302029
8.312030
8.312031
8.332032
8.342033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Hologic Inc.20.3
- QIAGEN N.V.18.0
- Roche Diagnostics5.7
- Becton16.7
- Dickinson and Company (BD)5.8
- Abbott Laboratories5.5
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Grade of Cervical Intraepithelial Neoplasia26.4%
Diagnostic Method18.6%
Treatment Type18.2%
Patient Demographics36.8%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.7
- Europe20.9
- Asia Pacific21.4
- Latin America14.2
- Middle East and Africa10.8
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Hologic Inc. | 94 | 78 | 79 | 90 | 75 | 88 | 84 |
| QIAGEN N.V. | 92 | 84 | 88 | 91 | 68 | 81 | 84 |
| Roche Diagnostics | 78 | 88 | 72 | 79 | 70 | 85 | 79 |
| Becton | 75 | 65 | 70 | 70 | 59 | 73 | 69 |
| Dickinson and Company (BD) | 66 | 75 | 69 | 53 | 76 | 66 | 68 |
| Abbott Laboratories | 70 | 60 | 52 | 61 | 52 | 62 | 60 |
| Thermo Fisher Scientific Inc. | 55 | 47 | 63 | 58 | 55 | 57 | 56 |
| Siemens Healthineers | 58 | 45 | 57 | 50 | 35 | 54 | 50 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Hologic Inc.
- QIAGEN N.V.
- Roche Diagnostics
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Hologic Inc. | ✓ | ✓ | ◐ | ◐ | ✓ | ◐ |
| QIAGEN N.V. | ✓ | ◐ | ✓ | ✓ | − | ✓ |
| Roche Diagnostics | ✓ | ✓ | ◐ | ◐ | − | ✓ |
| Becton | ◐ | ✓ | ◐ | ✓ | ◐ | − |
| Dickinson and Company (BD) | − | ◐ | ◐ | ◐ | ◐ | ◐ |
| Abbott Laboratories | ◐ | ◐ | ◐ | − | ◐ | − |
| Thermo Fisher Scientific Inc. | − | − | − | ◐ | ◐ | − |
| Siemens Healthineers | − | − | − | − | − | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Hologic Inc.84
2QIAGEN N.V.84
3Roche Diagnostics79
4Becton69
5Dickinson and Company (BD)68
6Abbott Laboratories60
7Thermo Fisher Scientific Inc.56
8Siemens Healthineers50
Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
Hologic Inc.QIAGEN N.V.Roche Diagnostics
Challenger2
Strong scale, closing on the leaders.
BectonDickinson and Company (BD)
Contender1
Focused players with pockets of strength.
Abbott Laboratories
Niche2
Specialists in a single segment or region.
Thermo Fisher Scientific Inc.Siemens Healthineers
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Grade of Cervical Intraepithelial Neoplasia in North America, then scale across Cervical Intraepithelial Neoplasia Market — a $132M beachhead inside a $2.01B market.
Beachhead (SOM)$132Mobtainable near-term
Serviceable (SAM)$774Mreachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion89 fit
CIN 1 (Mild Dysplasia)
Best fit — highest urgency & budget in Grade of Cervical Intraepithelial Neoplasia.
Economic buyer80 fit
CIN 2 (Moderate Dysplasia)
Strong fit — clear ROI and a fast path to value.
End user67 fit
CIN 3 (Severe Dysplasia/CIS)
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Grade of Cervical Intraepithelial Neoplasia in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Diagnostic Method & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Treatment Type
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales47%
Partner / channel25%
Digital / self-serve20%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Grade of Cervical Intraepithelial Neoplasia leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Cervical Intraepithelial Neoplasia Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified46%
Sales qualified23%
Evaluation14%
Closed-won8%
$13.3KCAC
$63KLTV
4.7:1LTV : CAC
< 2 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Cervical Intraepithelial Neoplasia Market is a high-growth opportunity — $3.20B by 2033, compounding at 10.5%.
TAM · 2025$1.44Btoday
TAM · 2033$3.20Bforecast
CAGR10.5%2027–2033
Cumulative$20.0Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$3.20BTotal addressable market
SAM$1.29BServiceable available market
SOM$216MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →10.5% CAGR
Demand compounds through 2033, outpacing GDP across Grade of Cervical Intraepithelial Neoplasia.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Grade of Cervical Intraepithelial Neoplasia moving from early to mainstream — durable secular demand.
Consolidation upside
14+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$3.20BLarge & growingTAM by 2033 at 10.5% CAGR
$1.29BServiceable nowreachable with today’s model
$216MBeachhead winobtainable near-term share
14+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$2.50BBear6.8% CAGR
$3.20BBase10.5% CAGR
$4.10BBull13.9% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Diagnostic Method optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Cervical Intraepithelial Neoplasia Market — a $5.93B market by 2033. Plan: grow share from 10.5% to 17.0%.
Market size · 2033$5.93Btotal addressable
Market CAGR8.4%2027–2033
Target share17.0%from 10.5% today
Revenue ambition$1.01Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 10.5% | 17.0% | Ahead |
| Revenue | $683M | $1.01B | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | Behind |
| Gross margin | 35.4% | 41.7% | Behind |
| Customer retention | 86.1% | 93.8% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Grade of Cervical Intraepithelial Neoplasia
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Diagnostic Method capability
A defensible second engine — invest in Diagnostic Method to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Grade of Cervical Intraepithelial Neoplasia share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Diagnostic Method
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $109M capacity & capability investment
- Greenlight bolt-on M&A in Diagnostic Method
- Authorise North America expansion plan
- Fund R&D program for Grade of Cervical Intraepithelial Neoplasia leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAhead
- Competitive share lossBehind
- Input-cost & supply riskAhead
- Regulatory / policy changeOn track
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Cervical Intraepithelial Neoplasia Market conversation — a $1.81B market you can size, segment and defend in minutes.
Market size · 2033$1.81Btotal opportunity
Growth4.0%CAGR to 2033
Addressable buyers1,363+accounts in scope
Typical ROI5.4×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Grade of Cervical Intraepithelial Neoplasia
Goal Grow share in Grade of Cervical Intraepithelial Neoplasia
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.4×return on cost, year one
< 4 mopayback period
$62K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
14+players profiled in this market
Coverage includes
Hologic Inc.QIAGEN N.V.Roche DiagnosticsBectonDickinson and Company (BD)Abbott LaboratoriesThermo Fisher Scientific Inc.Siemens Healthineers+6 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Cervical Intraepithelial Neoplasia Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Cervical Intraepithelial Neoplasia Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Cervical Lateral Mass Screw Fixator Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportCervical Occipital Plate Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportCervical Scraping Smear Market
Market size, share, segmentation and regional forecast.
$603M market · 2025 base year
View reportCervical Screening Market
Market size, share, segmentation and regional forecast.
$6.3B market · 2025 base year
View reportCervical Spine Heating Pad Market
Market size, share, segmentation and regional forecast.
$4.7B market · 2025 base year
View reportCervical Spine Retractor Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportCervical Spine System Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportCervical Total Disc Replacement Market
Market size, share, segmentation and regional forecast.
$4.2B market · 2025 base year
View reportCervical Total Disc Replacement Products Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportCervical Traction Device Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportCervical Treatment Instrument Market
Market size, share, segmentation and regional forecast.
$4.5B market · 2025 base year
View reportCervus And Cucumis Polypeptide Injection Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.